Biopharmaceuticals

Biologics now account for the majority of new molecular entity revenue, led by an exploding ADC pipeline (trastuzumab deruxtecan, datopotamab deruxtecan, sacituzumab govitecan) and a new generation of T-cell engagers including teclistamab, talquetamab, and tarlatamab. WCPD 2027 will cover next-generation ADC linker-payload chemistry, dual-payload and bispecific ADCs, and the rapid maturation of in-vivo CAR-T using LNP-delivered mRNA. Sessions will also address the anti-amyloid mAb class (lecanemab, donanemab) and reimbursement barriers, biosimilar uptake and interchangeability, allogeneic and iPSC-derived cell therapies, and the first AAV gene therapies entering broad use (Hemgenix, Elevidys, Roctavian).